Pfizer Inc. $PFE Shares Sold by Pzena Investment Management LLC

Pzena Investment Management LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 9.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,924,892 shares of the biopharmaceutical company’s stock after selling 601,908 shares during the quarter. Pzena Investment Management LLC’s holdings in Pfizer were worth $166,371,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Horizon Financial Services LLC raised its holdings in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. purchased a new stake in Pfizer during the fourth quarter worth approximately $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer in the fourth quarter worth $28,000. HFM Investment Advisors LLC raised its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Global Trust Asset Management LLC raised its stake in shares of Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 650 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.9%

Shares of NYSE PFE opened at $23.88 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The stock’s 50-day simple moving average is $25.74 and its 200-day simple moving average is $26.26. The firm has a market cap of $136.07 billion, a price-to-earnings ratio of 18.23 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the prior year, the business posted $0.92 EPS. The business’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer remains a possible beneficiary of growing investor interest in GLP-1 and obesity-treatment themes, with several recent pieces highlighting its weight-loss pipeline as a potentially underrated growth driver. Article Title
• Positive Sentiment: Commentary suggesting Pfizer may be undervalued has kept the stock on some investors’ watchlists, especially given its low valuation relative to its pipeline and dividend yield. Article Title
• Neutral Sentiment: Erste Group trimmed its FY2026 EPS estimate slightly to $2.95 from $2.96, a small change that adds to the cautious tone but is unlikely to materially alter the investment thesis on its own.
• Neutral Sentiment: Pfizer’s real-world COVID-19 vaccine study is nearing a data reveal, which could matter for sentiment, but the market impact is still uncertain until results are disclosed. Article Title
• Negative Sentiment: Recent coverage continues to emphasize Pfizer’s fading pandemic-era revenue stream, with Comirnaty and Paxlovid declines weighing on the company’s growth profile and investor sentiment. Article Title
• Negative Sentiment: Market coverage also noted the shares have been declining while the broader market improved, reinforcing the view that investors remain cautious on Pfizer near term. Article Title

Analysts Set New Price Targets

A number of brokerages recently weighed in on PFE. Guggenheim upped their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. HSBC upped their target price on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research report on Tuesday, June 9th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.